Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Clindamycin 1%-Benzoyl Peroxide 3% · 1 trial · 1 indication
Plasma concentrations of clindamycin in subjects with acne vulgaris
| Arm | Type | Description |
|---|---|---|
| Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel, | EXPERIMENTAL | Apply topically once daily; clindamycin (CLN); benzoyl peroxide (BPO); methylparaben-free (MPF) |
| Duac/ formulation 1 | ACTIVE_COMPARATOR | Apply topically once daily, Topical Gel (CLN 1%-BPO 5%), methylparaben-preserved |
| Duac/ formulation 2 | ACTIVE_COMPARATOR | Apply topically once daily, Duac Once Daily Gel (CLN 1%-BPO 5%), MPF |
| Name | Type | Description |
|---|---|---|
| Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel, | DRUG | Apply topically once daily |
Inclusion Criteria: * Capable of understanding and willing to provide signed and dated written voluntary informed consent (and HIPAA authorization) before any protocol-specific procedures were performed. Subjects under the legal age of consent in the state where the study was conducted must have pr...
Clindamycin 1%-Benzoyl Peroxide 3% is a topical small molecule combination product being developed by GSK plc for acne vulgaris. It combines clindamycin with benzoyl peroxide in a gel formulation. It is also known as Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel. It is investigational and has been studied in a Phase 1 clinical trial.
Clindamycin 1%-Benzoyl Peroxide 3% is being studied for the treatment of acne vulgaris. The single completed clinical trial enrolled participants with acne, aged 12 years and older, of all sexes. It is a topical dermatology product and is not yet approved for marketing.
GSK plc, which trades under the ticker GSK, is the developer of Clindamycin 1%-Benzoyl Peroxide 3% Gel. The company sponsored the Phase 1 bioavailability study of the product in acne vulgaris.
Clindamycin 1%-Benzoyl Peroxide 3% is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are ongoing. The product is investigational and has not been approved by the FDA for any indication.
Clindamycin 1%-Benzoyl Peroxide 3% has been evaluated in one completed Phase 1 trial, NCT01132443, titled W0261-101. It was a single-center, randomized, open-label, active-controlled bioavailability study in 72 subjects with acne vulgaris, comparing clindamycin bioavailability from the 3% gel, a 5% topical gel, and a 5% once-daily gel.
Yes. Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel is an alternative name for Clindamycin 1%-Benzoyl Peroxide 3%. Both refer to the same GSK topical acne product studied in the Phase 1 trial NCT01132443.